- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers
Qin Mei, George Wang, Jieying Liu, Yunying Chen, Jijie Gu, and Siwei Nie
Biologics Innovation and Discovery, WuXi Biologics
Anti-CD3 based T cell engager antibodies can redirect cytotoxic activity of T cells in a non-MHC restricted fashion to kill tumor cells effectively. Therefore, the discovery of an anti-CD3 antibody capable of activating T cells in the presence of tumor cells is highly desirable and in recent years, many anti-CD3 bispecific antibodies (bsAbs) entered clinical trials. Here, we showcase the discovery of an anti-CD3 monoclonal antibody (mAb) specific to a unique epitope on the epsilon chain of CD3 originating from the WuXi Biologics advanced hybridoma platform.
This scientific poster was originally presented during the 2023 Chinese Antibody Society Conference
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.